MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC).

Author:

Van Cutsem Eric1,Lenz Heinz-Josef2,Furuse Junji3,Tabernero Josep4,Heinemann Volker5,Ioka Tatsuya6,Bazin Igor7,Ueno Makoto8,Csõszi Tibor9,Wasan Harpreet10,Melichar Bohuslav11,Karasek Petr12,Macarulla Teresa Mercade13,Guillen Carmen14,Kalinka-Warzocha Ewa15,Horvath Zsolt16,Prenen Hans17,Schlichting Michael18,Ibrahim Ayman19,Bendell Johanna C.20

Affiliation:

1. University Hospitals Leuven, Leuven, Belgium;

2. University of Southern California, Los Angeles, CA;

3. Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan;

4. Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Barcelona, Spain;

5. Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Munich, Germany;

6. Hepatobiliary and Pancreatic Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan;

7. N. N. Blokhin Russian Cancer Research Center, Moscow, Russia;

8. Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan;

9. Jász-Nagykun Szolnok Megyei Hetényi Géza Kórház-Rendelointézet, Szolnok, Hungary;

10. Hammersmith Hospital, Imperial College, London, United Kingdom;

11. Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic;

12. Masaryk Memorial Cancer Institute, Brno, Czech Republic;

13. Vall d'Hebron Institute of Oncology, Barcelona, Spain;

14. Medical Oncology Department, Ramon y Cajal University Hospital, IRYCIS, RETICC of Spanish Ministry of Science and Innovation, Madrid, Spain;

15. Regional Oncology Center, Lodz, Poland;

16. University of Debrecen, Debrecen, Hungary;

17. Digestive Oncology Unit, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium;

18. Merck KGaA, Darmstadt, Germany;

19. EMD Serono, Billerica, MA;

20. Sarah Cannon Research Institute, Nashville, TN;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3